A uniform quantitative enzyme-linked immunosorbent assay for Coxsackievirus A16 antigen in vaccine

References

• Koh WM, Badaruddin H, La H, Chen MI, Cook AR. Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob Health. 2018;3(1):e000442. doi:10.1136/bmjgh-2017-000442. PMID: 29564154 eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhu R, Qian Y, Deng J, Sun Y, Liu L, Wang F, Zhao L. Comparing Enterovirus 71 with Coxsackievirus A16 by analyzing nucleotide sequences and antigenicity of recombinant proteins of VP1s and VP4s. BMC Microbiol. 2011;11(1):246. doi:10.1186/1471-2180-11-246. PMID: 22050722.
   PubMedGoogle Scholar
• Goto K, Sanefuji M, Kusuhara K, Nishimura Y, Shimizu H, Kira R, Torisu H, Hara T. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis. 2009;15(10):1689–91. doi:10.3201/eid1510.090594. PMID:19861078
   PubMed Web of Science ®Google Scholar
• Pan H, Zhu YF, Qi X, Zhang YJ, Li L, Deng F, Wu B, Wang SJ, Zhu FC, Wang H. Analysis on the epidemiological and genetic characteristics of enterovirus type 71 and Coxsackie A16 virus infection in Jiangsu, China [Article in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30(4):339–43. PMID: 19731523
   PubMedGoogle Scholar
• Yip CC, Lau SK, Zhou B, Zhang MX, Tsoi HW, Chan KH, Chen XC, Woo PC, Yuen KY. Emergence of enterovirus 71 “double-recombinant” strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol. 2010;155(9):1413–24. doi:10.1007/s00705-010-0722-0. PMID: 20549263; Epub 2010 Jun 13.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7(1):94. doi:10.1186/1743-422X-7-94. PMID: 20459851.
   PubMedGoogle Scholar
• Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):e75. doi:10.1038/emi.2016.73. PMID: 27436364
   PubMedGoogle Scholar
• Mao Q, Gao F, Wang Z, Li X, Gao Q, An W, Yang E, Bian L, Du R, Cui B, et al. Collaborative study on calibration and applicability of national antigen standard for coxsackievirus A16 vaccine [Article in Chinese]. Zhongguo Bing Du Bing Za Zhi. 2018;8(6):59–64. doi:10.16505/j.2095-0136.2018.0107.
   Google Scholar
• Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012;86(22):11967–76. doi:10.1128/JVI.00902-12. PMID: 22951825. Epub 2012 Sep 5.
   PubMed Web of Science ®Google Scholar
• Du R, Mao Q, Hu Y, Lang S, Sun S, Li K, Gao F, Bian L, Yang C, Cui B, et al. A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge. Hum Vaccin Immunother. 2019;15(10):2343–50. doi:10.1080/21645515.2019.1565266. PMID: 30735461
   PubMed Web of Science ®Google Scholar
• Ye X, Yang L, Jia J, Han J, Li S, Liu Y, Xu L, Zhao H, Chen Y, Y L, et al. Development of sandwich ELISAs that can distinguish different types of coxsackievirus A16 viral particles. Appl Microbiol Biotechnol. 2016;100(6):2809–15. doi:10.1007/s00253-016-7296-z. PMID: 26767830
   PubMed Web of Science ®Google Scholar
• He M, Xu L, Zheng Q, Zhu R, Yin Z, Zha Z, Lin Y, Yang L, Huang Y, Ye X, et al. Identification of antibodies with non-overlapping neutralization sites that target coxsackievirus A16. Cell Host Microbe. 2020;27(2):249–61. doi:10.1016/j.chom.2020.01.003. PMID: 32027857
   PubMed Web of Science ®Google Scholar
• Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28. doi:10.1056/NEJMoa1304923. PMID: 24571754
   PubMed Web of Science ®Google Scholar
• Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–37. doi:10.1056/NEJMoa1303224. PMID: 24571755
   PubMed Web of Science ®Google Scholar
• Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024–32. doi:10.1016/S0140-6736(13)61049-1. PMID: 23726161; Epub 2013 May 29.
   PubMed Web of Science ®Google Scholar
• National outline of epidemic situation of statutory infectious diseases [Internet]. [cited 2015 Aug 11]. http://www.nhc.gov.cn/jkj/s3578/201901/7ba54ed285484474a881584606aa8c94.shtml.
   Google Scholar
• Cai Y, Liu Q, Huang X, Li D, Ku Z, Zhang Y, Huang Z. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine. 2013;31(18):2215–21. doi:10.1016/j.vaccine.2013.03.007. PMID: 23499596. Epub 2013 Mar 13.
   PubMed Web of Science ®Google Scholar
• Li J, Liu G, Liu X, Yang J, Chang J, Zhang W, Yu XF. Optimization and characterization of candidate strain for coxsackievirus A16 inactivated vaccine. Viruses. 2015;7(7):3891–909. doi:10.3390/v7072803. PMID: 26193302
   PubMed Web of Science ®Google Scholar
• Lim H, In HJ, Lee JA, Sik Yoo J, Lee SW, Chung GT, Choi YK, Chung JK, Cho SJ, Lee JW. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36(24):3445–52. doi:10.1016/j.vaccine.2018.05.005. PMID: 29739716. Epub 2018 May 5.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30(47):6642–48. doi:10.1016/j.vaccine.2012.08.071. PMID: 22959985. Epub 2012 Sep 7.
   PubMed Web of Science ®Google Scholar
• Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, Li D, Jin X, An W, Huang Z. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32(34):4296–303. doi:10.1016/j.vaccine.2014.06.025. PMID: 24950363. Epub 2014 Jun 17.
   PubMed Web of Science ®Google Scholar
• Poirier B, Variot P, Delourme P, Maurin J, Morgeaux S. Would an in vitro ELISA test be a suitable alternative potency method to the in vivo immunogenicity assay commonly used in the context of international Hepatitis A vaccines batch release? Vaccine. 2010;28(7):1796–802. doi:10.1016/j.vaccine.2009.12.006. PMID: 20018270 Epub 2009 Dec 16.
   PubMed Web of Science ®Google Scholar